BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• Business

  Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)

  Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced financial results for the three months ended March 31, 2023.

  May 4, 2023

   · 

  13 min read
• Business

  Cerus Corporation Announces First Quarter 2023 Financial Results

  Cerus Corporation announced financial results for the first quarter ended March 31, 2023.

  May 4, 2023

   · 

  17 min read
• Business

  Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress

  Rocket Pharmaceuticals, Inc. reported financial results for the quarter ending March 31, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.

  May 4, 2023

   · 

  14 min read
• Business

  DermTech Reports First-Quarter 2023 Financial Results

  Covered lives increased to 126 million Cash runway through the third quarter of 2024 DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported its first-quarter 2023 financial results.

  May 4, 2023

   · 

  9 min read
• Business

  Ligand Reports First Quarter 2023 Financial Results

  Ligand Pharmaceuticals Incorporated reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates.

  May 4, 2023

   · 

  23 min read
• Policy

  Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance for Monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence

  Nucleix has received 510 clearance from the U.S. Food and Drug Administration to market Bladder EpiCheck® for use as a non-invasive method for surveillance of tumor recurrence in patients previously diagnosed with non-muscle invasive bladder cancer, in conjunction with cystoscopy.

  May 4, 2023

   · 

  4 min read
• Business

  Pro-Dex, Inc. Announces Fiscal 2023 Third Quarter and Nine-Month Results

  PRO-DEX, INC. announced financial results for its fiscal 2023 third quarter ended March 31, 2023.

  May 4, 2023

   · 

  8 min read
• Business

  Globus Medical Reports First Quarter 2023 Results

  Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the quarter ended March 31, 2023.

  May 4, 2023

   · 

  17 min read
• Business

  Panbela Provides Business Update and Reports Q1 2023 Financial Results

  Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, provides a business update and reports financial results for the quarter ended March 31, 2023.

  May 4, 2023

   · 

  12 min read
• Biotech Bay

  4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock - May 04, 2023

  4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.

  May 4, 2023

   · 

  5 min read